^
BIOMARKER:

RET rearrangement

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Entrez ID:
RET rearrangement
NSCLC
cabozantinib tablet
Sensitive: A2 - Guideline
RET rearrangement
NSCLC
vandetanib
Sensitive: A2 - Guideline
RET rearrangement
NSCLC
selpercatinib
Sensitive: A2 - Guideline
RET rearrangement
NSCLC
pralsetinib
Sensitive: A2 - Guideline
RET rearrangement
NSCLC
alectinib
Sensitive: C2 – Inclusion Criteria
RET rearrangement
NSCLC
sunitinib
Sensitive: C2 – Inclusion Criteria
RET rearrangement
NSCLC
selpercatinib + pralsetinib
Sensitive: C3 – Early Trials
RET rearrangement
LUAD
cabozantinib tablet
Sensitive: C3 – Early Trials
RET rearrangement
Thyroid Gland Carcinoma
selumetinib
Sensitive: D – Preclinical
RET rearrangement
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
RET rearrangement
Thyroid Gland Carcinoma
AZD1480
Sensitive: D – Preclinical